PwC joins the Medicines Manufacturing Innovation Centre
In forming the partnership, PwC will join the founding partners of the Medicines Manufacturing Innovation Centre - CPI, the University of Strathclyde, GSK and AstraZeneca - to address challenges and maximise technology opportunities in the pharmaceutical supply chain.
The programme which is part-funded by Innovate UK and Scottish Enterprise, will strive to achieve this via its flagship project ‘Grand Challenge’. Which strive to advance emerging and disruptive technologies.
“We are excited to join the team at the Medicines Manufacturing Innovation Centre bringing PwC’s insights, experiences and connections. We are confident that this collaboration will have a big impact on the future of pharmaceutical manufacturing,” Johnathon Marshall, UK Pharma and Life Science Consulting lead at PwC.
What will PwC bring to the programme?
As part of the agreement, PwC plans to contribute significant value to the consortium by increasing business development opportunities, leveraging its global connectivity and brand authority.
In addition, PwC will act as a scout for new disruptive innovations, organisations and global opportunities, as well as develop market analysis and studies to communicate the value of current and future projects, and seek funding from private investors, industry and government.
“By partnering with PwC, the Medicines Manufacturing Innovation Centre will be able to work smarter, better and faster, ensuring more value to patients and the economy while advancing the UK’s already strong medicines manufacturing industry even further,” added Dave Tudor, Managing Director of the Medicines Manufacturing Innovation Centre, Biologics & Quality at CPI.
“This partnership will support the Medicines Manufacturing Innovation Centre to reach new innovative organisations and markets, leading to more opportunities for industry to collaborate on next-generation technology,” concluded Neil Sheddan, Business Development Director at the Medicines Manufacturing Innovation Centre at CPI.